The quarter in brief
UnitedHealth Group reported third-quarter 2026 results on October 13. Revenues were $112.7 billion, compared with $113.2 billion a year earlierUnitedHealth Group results, a slight decline. Profit recovered sharply: earnings from operations were $6.6 billionHighlights, and EPS was $4.56, with adjusted EPS of $4.69Highlights, up from $2.59 and $2.92 in the third quarter of 2025Statements of operations. Analysts had expected adjusted EPS of $4.14, according to LSEG data cited by ReutersTIKR.
The improvement came from pricing and cost discipline on the insurance side. The medical care ratio was 88.4%, compared with 89.9% a year earlierUnitedHealth Group results, and the operating cost ratio was 12.8%, compared with 13.5%Release.
Both segments widened their margins. UnitedHealthcare's operating margin was 3.3%, against 2.1% a year earlierUnitedHealthcare, and Optum's was 5.6%, against 3.6%Earnings by Business. Within Optum, Optum Insight's earnings from operations rose to $1.3 billion from $920 millionOptum Insight, and Optum Rx earned $1.7 billion, up from $1.5 billionOptum Rx.
Cash generation was solid. Operating cash flow was $5.1 billion, or 1.2 times net incomeCash flow, and the company has repurchased $5.0 billion of stock and paid $6.2 billion in dividends so far this yearCash flow.
What changed in the thesis
The outlook went up again. UnitedHealth now expects 2026 adjusted EPS of at least $20.50 and GAAP EPS of at least $19.50Outlook. That is the third raise this year: in April the outlook was raised to greater than $17.35 a share and greater than $18.25 adjustedHeadline, and in July the ranges were $18.45 to $18.95 GAAP and $19.50 to $20.00 adjustedQ2 release. It suggests that the pricing and cost actions are working.
Management framed 2027 for the first time. The CFO said analyst consensus for 2027 "may understate the opportunity ahead" and called the lower end of the company's long-term 13% to 16% growth rate "a more reasonable starting point"Wayne DeVeydt remarks. On the 2026 floor, 13% growth would mean about $23.17 of adjusted EPS in 2027 (our arithmetic). A more comprehensive update on the outlook for next year is promised before year endSteve Hemsley closing remarks.
The quality of the beat is mixed. The medical care ratio benefited from $610 million of favorable prior-period reserve development related to 2026 dates of serviceMetrics. On our arithmetic, that is worth roughly 53 cents a share after tax, using the quarter's tax provision of $1,224 million on pre-tax earnings of $5,524 millionStatements of operations (a 22.2% rate) and 902 million diluted shares. That is about the size of the 55-cent beat against consensus. The ratio also rose from 86.7% in the second quarterQ2 release, as it typically does through the year.
Volume is going the wrong way. UnitedHealthcare served 48.3 million people, and its Employer & Individual business lost 165,000 people in the quarter to employer attritionUnitedHealthcare; Employer & Individual. Optum Health revenue fell 10% to $22.9 billion, with an operating margin of 3.2%Optum Health, and Optum Rx adjusted scripts were 393 million, against 414 million a year agoOptum Rx. Earnings growth is coming from margin repair on a shrinking base, which has a natural limit.
Cost trend has not eased. The head of UnitedHealthcare said commercial benefit trends are exceeding the initial expectation of 11%Tim Noel remarks, and the CFO said the company remains "respectful of continued elevated utilization trends"Wayne DeVeydt remarks.
Bull and bear
2027 guidance lands at the top of the 13–16% range as Medicare Advantage repricing and Optum Health restructuring keep lifting margins. Buybacks resume at scale, and the market pays about 19x for a recovered compounder, roughly $452.
Medical cost trend stays above plan, the reserve releases that flattered 2026 do not repeat, and membership keeps shrinking into 2027. Growth comes in near 10% and the multiple slips to 16x, roughly $361.
Our scenarios are not symmetric: the bear value sits about $56 below the base value, the bull value about $35 above it. The bull case needs management to beat its own new framing, while the bear case needs only cost trend to stay where management says it is today.
Formal 2027 guidance at or above the top of the 13–16% range, with membership stabilizing, would make us bullish. Guidance below 13%, or a medical care ratio that rises in the fourth quarter beyond normal seasonality, would make us bearish.
Valuation
The company's numbers frame the valuation. The 2026 adjusted EPS floor is $20.50Outlook, and diluted weighted-average shares were 902 million in the quarterStatements of operations. Applying management's 13% to 16% range gives illustrative 2027 adjusted EPS of about $23.17 to $23.78. That is our arithmetic, not company guidance.
| Scenario | 2027 adjusted EPS | Multiple | Value per share |
|---|---|---|---|
| Bear: growth near 10% | ≈ $22.55 | 16x | ≈ $361 |
| Base: low end of 13–16% | ≈ $23.17 | 18x | ≈ $417 |
| Bull: top of 13–16% | ≈ $23.78 | 19x | ≈ $452 |
The base case lands close to where the shares traded before publication. We see no edge in either direction at this level.
The call
Neutral on UNH for 12 months, no price target, moderate conviction. The turnaround is working: margins are up in both segments, the outlook has been raised three times and cash flow funds the dividend and buybacks comfortably. But a shrinking revenue base, a reserve-aided beat and commercial trend above plan mean the next leg depends on 2027 guidance that we haven't seen yet. We will revisit when it is published.
This is the author's opinion, not investment advice. Figures are from UnitedHealth Group's Q3, Q2 and Q1 2026 earnings releases and its Q3 call prepared remarks; the consensus figure is from LSEG via Reuters, as reported by TIKR. Scenario values are our own.
Discussion
Loading comments…